var data={"title":"Liposomal amphotericin B: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Liposomal amphotericin B: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5636?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">see &quot;Liposomal amphotericin B: Drug information&quot;</a> and <a href=\"topic.htm?path=liposomal-amphotericin-b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Liposomal amphotericin B: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673687\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AmBisome</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134882\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>AmBisome</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045142\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12857681\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection.</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> In neonates, lipid formulations of amphotericin have poorer penetration into the central nervous system, kidneys, urinary tract, and eyes than conventional amphotericin and are not preferred in most cases (IDSA [Pappas 2016]; <i>Red Book</i> [AAP 2015]; Turkova 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Candidiasis,</b>\n      <b> invasive (non-CNS):</b> Limited data available: IV: 3 to 5 mg/kg/dose once daily (Cetin 2005; IDSA [Pappas 2016]; Juster-Reicher 2003; Queiroz-Telles 2008); treatment should continue for at least 2 weeks after the first negative blood culture and signs and symptoms have resolved (IDSA [Pappas 2016]); doses as high as 7 mg/kg/dose once daily have been used (Juster-Reicher 2003); another report describes a dose escalation approach with dosing initiated with 1 mg/kg/dose on day 1 and increased by 1 mg/kg/dose once daily to a maximum of 5 mg/kg/dose once daily (preterm neonate: n=40; term neonate: n=4) (Scarcella 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis,</b>\n      <b> CNS infection: </b>IV: 5 mg/kg/dose once daily; may add flucytosine if there is no clinical response (IDSA [Pappas 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045135\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">see &quot;Liposomal amphotericin B: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection.</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Pediatric: <b>Note:</b> Premedication: For patients who experience nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: NSAID (with or without diphenhydramine) <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Empiric therapy: Infants, Children, and Adolescents: IV: 3 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment, susceptible systemic infection: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Aspergillosis</i></b>\n      <b>, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Invasive: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily (IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: Children and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blastomycosis</b>\n      <b>, invasive:</b> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily for initial therapy, if CNS infection 4 to 6 weeks may be needed; followed by oral itraconazole for a total of 12 months (IDSA [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis</b>\n      <b>, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Invasive (Independent of HIV status): Infant, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily (Filioti 2007; IDSA [Pappas 2016]); <b>Note:</b> In HIV-exposed/-positive patients, doses at the higher end of the range may be considered (5 mg/kg/day) (HHS [OI pediatric 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CNS infection: Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily with or without flucytosine (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015]; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Esophageal: HIV-exposed/-positive: Adolescents: IV: 3 to 4 mg/kg/dose once daily for 14 to 21 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Coccidioidomycosis</i></b>\n      <b>, invasive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Disseminated infection, nonpulmonary:</i> Infants, Children, and Adolescents: IV: 2 to 5 mg/kg/dose once daily with or without concomitant azole antifungal (IDSA [Galgiani 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pulmonary infection, diffuse: </i>Infants, Children, and Adolescents: IV: 2 to 5 mg/kg/dose once daily for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months (IDSA [Galgiani 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive: <i>Non-CNS infection, severe (ie, diffuse pulmonary or severely ill with extrathoracic, disseminated disease):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 5 mg/kg/dose once daily until clinical improvement (minimum of several weeks of therapy), then initiate triazole therapy (eg, fluconazole or itraconazole); dose may be increased to as high as 10 mg/kg/dose once daily for life-threatening infection (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 3 to 5 mg/kg/dose once daily until clinical improvement, then switch to fluconazole or itraconazole (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Cryptococcosis</i></b>\n      <b>, invasive: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Disseminated cryptococcosis (non-CNS or severe pulmonary disease):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children (independent of HIV status): IV: 3 to 5 mg/kg/dose once daily with oral flucytosine; if flucytosine unavailable or not tolerated, may administer alone or in combination with high-dose fluconazole in HIV-exposed/-positive patients (HHS [OI pediatric 2016]; IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive: IV: 3 to 4 mg/kg/dose once daily for at least 14 days; may consider addition of oral flucytosine (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: IV: 3 to 4 mg/kg/dose once daily with or without flucytosine or fluconazole (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Non-HIV-exposed/-positive: Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily with flucytosine (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer&rsquo;s labeling: Infants, Children, and Adolescents: IV: 6 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants and Children: IV: 6 mg/kg/dose once daily with or without oral flucytosine or high dose fluconazole for a minimum 2-week induction; <b>Note:</b> Minimum 2-week induction, followed by consolidation and chronic suppressive therapy; a longer duration of induction therapy may be necessary if CSF is not negative or lack of clinical improvement (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Adolescents: IV: 3 to 4 mg/kg/dose once daily with or without oral flucytosine or fluconazole (HHS [OI adult 2016]); doses up to 6 mg/kg/dose have been reported for treatment of meningoencephalitis and may be considered for treatment failure or high fungal burden disease (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Febrile neutropenia, empiric therapy: </b>Infants, Children, and Adolescents: IV: 3 mg/kg/dose once daily (Caselli 2012; IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive: <i>Acute pulmonary disease or disseminated (non-CNS):</i> Infants, Children, and Adolescents: IV: 3 mg/kg/dose once daily for 1 to 2 weeks followed by oral itraconazole for a total of 12 weeks; conventional amphotericin B typically preferred (IDSA [Wheat 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Disseminated infection (non-CNS disease):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: IV: 3 to 5 mg/kg/dose once daily for at least 2 weeks for induction; if itraconazole not tolerated for consolidation therapy, may continue for 4 to 6 weeks (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: IV: 3 mg/kg/dose once daily for at least 2 weeks for induction (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>CNS disease:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily for 4 to 6 weeks for induction, followed by consolidation therapy (HHS [OI adult 2016]; HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Visceral infection, treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immunocompetent patients: Infants, Children, and Adolescents: IV: Initial: 3 mg/kg/dose once daily on days 1 to 5 and 3 mg/kg/dose on days 14 and 21. <b>Note:</b> Repeat course may be given to patients who do not achieve parasitic clearance.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immunocompromised patients: Infants, Children, and Adolescents: IV: Initial: 4 mg/kg/dose once daily on days 1 to 5 and 4 mg/kg/dose on days 10, 17, 24, 31, 38</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Treatment: Adolescents: IV: 2 to 4 mg/kg/dose once daily or an interrupted schedule of 4 mg/kg/dose on days 1 to 5, and on days 10, 17, 24, 31, and 38 to achieve a <b>total</b> <b>dose</b> of 20 to 60 mg/kg (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Chronic maintenance therapy: Adolescents: IV: 4 mg/kg/dose every 2 to 4 weeks; <b>Note:</b> Use reserved for patients with visceral infection and CD4 count &lt;200 cells/mm<sup>3 </sup>(HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cutaneous infection, treatment; HIV-exposed/-positive: Adolescents: IV: 2 to 4 mg/kg/dose once daily for 10 days or an interrupted schedule of 4 mg/kg/dose on days 1 to 5, and on days 10, 17, 24, 31, and 38 to achieve a <b>total</b> <b>dose</b> of 20 to 60 mg/kg (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sporotrichosis</b>\n      <b> infection </b>(IDSA [Kauffman 2007])<b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Disseminated, pulmonary or osteoarticular disease: Adolescents: IV: 3 to 5 mg/kg/dose once daily, followed by oral itraconazole after a favorable response is seen with amphotericin initial therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningeal: Adolescents: IV: 5 mg/kg/dose once daily for 4 to 6 weeks, followed by oral itraconazole</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Premedication: For patients who experience nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: NSAID (with or without diphenhydramine) <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered. <b>General dosing, susceptible infection:</b> IV: 3 to 6 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; has been successfully administered to adult patients with preexisting renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Poorly dialyzed; Adults: No dosage adjustments necessary (Heintz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH/CVVHD/CVVHDF: Adults: No dosage adjustments necessary (Heintz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673688\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AmBisome: 50 mg (1 ea) [contains cholesterol, distearoyl phosphatidylglycerol, hydrogenated soy phosphatidylcholine, sodium succinate hexahydrate, sucrose, tocopherol, dl-alpha]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134852\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045145\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: Do not use in-line filter less than 1 micron to administer AmBisome. Flush line with D5W prior to infusion; infusion of diluted AmBisome should start within 6 hours of preparation; infuse over 2 hours; infusion time may be reduced to 1 hour in patients who tolerate the treatment. If the patient experiences discomfort during infusion, the duration of infusion may be increased. Discontinue if severe respiratory distress occurs.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related reactions, premedicate with the following drugs, 30 to 60 minutes prior to drug administration: A nonsteroidal (eg, ibuprofen,) &plusmn; diphenhydramine or acetaminophen with diphenhydramine or hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134878\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Store intact vials at &le;25&deg;C (&le;77&deg;F). Reconstituted vials are stable at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 24 hours. Do not freeze. Begin infusion within 6 hours of dilution with D<sub>5</sub>W. Extended storage information may be available; contact product manufacturer to obtain current recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045144\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Empirical therapy for presumed fungal infection in febrile, neutropenic patients; treatment of patients with <i>Aspergillus</i> species, <i>Candida</i> species, and/or <i>Cryptococcus</i> species infections refractory to amphotericin B desoxycholate (conventional amphotericin), or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B desoxycholate; treatment of cryptococcal meningitis in HIV-infected patients; treatment of visceral leishmaniasis (all indications: FDA approved in ages &ge;1 month and adults); has also been used for treatment of systemic <i>Histoplasmosis</i> infection, blastomycosis, coccidioidomycosis, and <i>Sporotrichosis</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134910\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:2em;\">AmBisome may be confused with Ambisolm, Ambisom</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (Amphocin, Fungizone) or with other lipid-based amphotericin formulations (Abelcet, Amphotec)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134907\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Nephrotoxicity and infusion-related hyperpyrexia, rigor, and chilling are reduced relative to amphotericin deoxycholate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation, bradycardia, cardiac arrest, cardiac arrhythmia, cardiomegaly, chest pain, edema, facial edema, flushing, heart valve disease, hypertension, hypotension, localized phlebitis, orthostatic hypotension, peripheral edema, tachycardia, vascular disorder, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormality in thinking, agitation, anxiety, chills, coma, confusion, depression, dizziness, drowsiness, dysesthesia, dystonia, hallucination, headache, insomnia, malaise, nervousness, pain, paresthesia, rigors, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, cellulitis, dermal ulcer, dermatological reaction, diaphoresis, maculopapular rash, pruritus, skin discoloration, skin rash, urticaria, vesiculobullous dermatitis, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, hyperchloremia, hyperglycemia, hyperkalemia, hypermagnesemia, hypernatremia, hyperphosphatemia, hypervolemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, increased lactate dehydrogenase, increased nonprotein nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, aphthous stomatitis, constipation, diarrhea, dyspepsia, dysphagia, enlargement of abdomen, eructation, fecal incontinence, flatulence, gastrointestinal hemorrhage, gingival hemorrhage, hematemesis, hemorrhoids, hiccups, increased serum amylase, intestinal obstruction, mucositis, nausea, rectal disease, stomatitis, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Dysuria, hematuria, nephrotoxicity, toxic nephrosis, urinary incontence, vaginal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, blood coagulation disorder, bruise, decreased prothrombin time, hemophthalmos, hemorrhage, hypoproteinemia, increased prothrombin time, leukopenia, oral hemorrhage, petechia, purpura, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests (not specified), hepatic injury, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatomegaly, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Delayed hypersensitivity, hypersensitivity reaction, transfusion reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Graft versus host disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, herpes simplex infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Inflammation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, myalgia, neck pain, ostealgia, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Conjunctivitis, dry eyes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute renal failure, increased blood urea nitrogen, increased serum creatinine, renal failure, renal function abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, atelectasis, cough, dry nose, dyspnea, epistaxis, flu-like symptoms, hemoptysis, hyperventilation, hypoxia, pharyngitis, pleural effusion, pneumonia, pulmonary disease, pulmonary edema, respiratory alkalosis, respiratory failure, respiratory insufficiency, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Infusion related reactions (fever, chills, vomiting, nausea, dyspnea, tachycardia, hypertension, vasodilation, hypotension, hyperventilation, hypoxia), procedural complication</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Agranulocytosis, angioedema, cyanosis, hemorrhagic cystitis, hypoventilation, rhabdomyolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134872\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amphotericin B deoxycholate or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134856\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If a severe anaphylactic reaction occurs, the infusion should be immediately discontinued; the patient should not receive further infusions. Administer under close clinical observation during initial dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Acute reactions (including fever and chills) may occur 1 to 3 hours after starting infusions; reactions are more common with the first few doses and generally diminish with subsequent doses. Immediately discontinue infusion if a severe anaphylactic reaction occurs; the patient should not receive further infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukocyte transfusions: Acute pulmonary toxicity has been reported in patients receiving simultaneous leukocyte transfusions and amphotericin B.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298746\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134861\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12669&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Stibogluconate: Amphotericin B may enhance the cardiotoxic effect of Sodium Stibogluconate. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134863\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6866584\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women; refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmus 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045141\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BUN, serum creatinine, liver function tests, serum electrolytes (particularly magnesium and potassium), CBC, vital signs, I &amp; O; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134855\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman 1992).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134871\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Exhibits nonlinear kinetics (greater than proportional increase in serum concentration with an increase in dose) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.1 to 0.16 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 7 to 10 hours (following a single 24-hour dosing interval); Terminal half to life: 100 to 153 hours (following multiple dosing up to 49 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15589751\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">The lipid portion of amphotericin B (liposomal) formulation contains 0.27 kcal per 5 mg; for patients receiving parenteral nutrition, adjustment to the amount of lipids may be necessary (Sacks 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322989\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (AmBisome Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $272.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038526\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AmBisome (AE, AR, AT, AU, BE, CH, CY, DE, DK, ES, ET, FI, FR, GB, GR, HK, HN, IE, IL, IT, JP, KR, KW, LB, LU, LV, MT, NL, NO, PL, PT, PY, QA, RU, SA, SE, SG, TH, TR, TW);</li>\n      <li>Ambisome (BB, BR, HU, IS, SI);</li>\n      <li>Amfostat (MX);</li>\n      <li>Amphotec (CN);</li>\n      <li>Fengkesong (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: A scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caselli D, Cesaro S, Ziino O, et al. A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children. <i>Br J Haematol</i>. 2012;158(2):249-255.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/22571507/pubmed\" target=\"_blank\" id=\"22571507\">22571507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cetin H, Yalaz M, Akisu M, et al, &quot;The Efficacy of Two Different Lipid-Based Amphotericin B in Neonatal Candida Septicemia,&quot; <i>Pediatr Int</i>, 2005, 47(6):676-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/16354223/pubmed\" target=\"_blank\" id=\"16354223\">16354223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al, &quot;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2008, 46(12):1801-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emminger W, Graninger W, Emminger-Schmidmeir W, et al, &ldquo;Tolerance of High Doses of Amphotericin B by Infusion of a Liposomal Formulation in Children With Cancer,&rdquo; <i>Ann Hematol</i>, 1994, 68:27-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/8110875/pubmed\" target=\"_blank\" id=\"8110875\">8110875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filioti J, Spiroglou K, Panteliadis CP, et al, &quot;Invasive Candidiasis in Pediatric Intensive Care Patients: Epidemiology, Risk Factors, Management, and Outcome,&quot; <i>Intensive Care Med</i>, 2007, 33(7):1272-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/17503015/pubmed\" target=\"_blank\" id=\"17503015\">17503015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al, &quot;Coccidioidomycosis,&quot; <i>Clin Infect Dis</i>, 2005, 41(9):1217-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/16206093/pubmed\" target=\"_blank\" id=\"16206093\">16206093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. December 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11705428/pubmed\" target=\"_blank\" id=\"11705428\">11705428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. November 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed December 5, 2016<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11705428/pubmed\" target=\"_blank\" id=\"11705428\">11705428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juster-Reicher A, Flidel-Rimon O, Amitay M, &quot;High-Dose Liposomal Amphotericin B in the Therapy of Systemic Candidiasis in Neonates,&quot; <i>Eur J Clin Microbiol Infect Dis</i>, 2003, 22(10):603-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman CA, Bustamante B, Chapman SW, et al, &quot;Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(10):1255-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/17968818/pubmed\" target=\"_blank\" id=\"17968818\">17968818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King CT, Rogers PD, Cleary JD, et al, &quot;Antifungal Therapy During Pregnancy,&quot; <i>Clin Infect Dis</i>, 1998, 27(5):1151-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9827262/pubmed\" target=\"_blank\" id=\"9827262\">9827262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/28459614/pubmed\" target=\"_blank\" id=\"28459614\">28459614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mactal-Haaf C, Hoffman M, and Kuchta A, &quot;Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,&quot; <i>J Hum Lact</i>, 2001, 17(2):160-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/11847833/pubmed\" target=\"_blank\" id=\"11847833\">11847833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016 ;63(4):e1-e60,<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/27365388/pubmed\" target=\"_blank\" id=\"27365388\">27365388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &quot;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Queiroz-Telles F, Berezin E, Leverger G, et al, &quot;Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis: Substudy of a Randomized Double-Blind Trial,&quot; <i>Pediatr Infect Dis J</i>, 2008, 27(9):820-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/18679151/pubmed\" target=\"_blank\" id=\"18679151\">18679151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sacks GS and Cleary JD, &quot;Nutritional Impact of Lipid-Associated Amphotericin B Formulations,&quot; <i>Ann Pharmacother</i>, 1997, 31(1):121-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/8997484/pubmed\" target=\"_blank\" id=\"8997484\">8997484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scarcella A, Pasquariello MB, Giugliano B, et al, &quot;Liposomal Amphotericin B Treatment for Neonatal Fungal Infections,&quot; <i>Pediatr Infect Dis J</i>, 1998, 17(2):146-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/9493812/pubmed\" target=\"_blank\" id=\"9493812\">9493812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Glaser CA, Bloch KC, et al, &quot;The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2008, 47(3):303-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/18582201/pubmed\" target=\"_blank\" id=\"18582201\">18582201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? <i>Curr Opin Infect Dis</i>. 2011;24(2):163-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/21301335 /pubmed\" target=\"_blank\" id=\"21301335 \">21301335 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Finberg RW, Arndt C, et al, &ldquo;Liposomal Amphotericin B for Empirical Therapy in Patients With Persistent Fever and Neutropenia,&rdquo; <i>N Engl J Med,</i> 1999, 340:764-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/10072411/pubmed\" target=\"_blank\" id=\"10072411\">10072411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat LJ, Freifeld AG, Kleiman MB, et al, &quot;Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(7):807-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-pediatric-drug-information/abstract-text/17806045/pubmed\" target=\"_blank\" id=\"17806045\">17806045</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12669 Version 127.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24673687\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134882\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045142\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12857681\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045135\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24673688\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F134852\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045145\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F134878\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045144\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134910\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134907\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134872\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134856\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298746\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134861\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134863\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6866584\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045141\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134855\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F134871\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F15589751\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322989\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038526\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12669|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">Liposomal amphotericin B: Drug information</a></li><li><a href=\"topic.htm?path=liposomal-amphotericin-b-patient-drug-information\" class=\"drug drug_patient\">Liposomal amphotericin B: Patient drug information</a></li></ul></div></div>","javascript":null}